Remedy Entertainment Plc | Stock Exchange Release 9.30 am (EEST) May 31, 2022

Remedy Entertainment Plc applies for listing of option rights 2019

Remedy Entertainment Plc (the “Company”) will apply for the listing of its 2019 option rights on the Nasdaq Helsinki Ltd First North Growth marketplace as of June 1, 2022.

A total number of 400,000 option rights 2019 have been issued. Remedy Entertainment Plc has cancelled a total of 29,000 option rights 2019 held by the Company. After the cancellation, the remaining 371,000 option rights 2019 entitle holders to subscribe for 371,000 Company shares.

Each option rights entitles its holder to subscribe to one (1) Company’s share. Share subscription for with the option rights must be at least 1,000 shares.

The share subscription price under the 2019 option rights is EUR 9.23 per share. The shares will be subscribed for with the option rights against payment. 

If the Company, after granting the options but before the share subscription, decides on distribution of dividends or other profits to its shareholders, the subscription price of the shares to be subscribed for with the options will not be changed. If the Company, after issuing the options but before the share subscription, decides to decrease its share capital, the subscription price of the shares to be subscribed for with the options shall be decreased with the amount of distributable share capital on the record date of the repayment of the share capital.

The share subscription period for 2019 option rights shall begin on June 1, 2022 and terminate on May 31, 2025. The option rights will be freely transferable on June 1, 2022.

 The share subscription period is divided into the following subscription windows:

  • 2022: from June 1 until September 15 and from September 16 until December 31
     
  • 2023: from January 2 until March 31, from April 1 until May 31, from June 1 until September 15 and from September 16 until December 31
     
  • 2024: from January 2 until March 31, from April 1 until May 31, from June 1 until September 15 and from September 16 until December 31
     
  • 2025: from January 2 until March 31 and from April 1 until May 31

The option holders can subscribe the shares during the subscription period by giving the payment and subscription details to their own bank.

The Board of Directors shall resolve on the acceptance of share subscriptions in its regular meetings and shall file the new shares for registration with the Trade Register after the respective subscription window has ended. New shares subscribed with options rights 2019 will be listed as additional lots of Company shares on the Nasdaq Helsinki Ltd Main list together with the old shares after the shares increase has been registered.

New shares shall entitle to full dividend from the beginning of the accounting period, during which they have been registered to the Trade Register. Other shareholder rights shall begin immediately after the new shares have been registered to the Trade Register.

If the Option Holder receives existing shares held by the Company, the right to the dividend and other shareholder rights shall begin when the shares have been recorded to his/her book-entry account.

The grounds for the granting of the 2019 option rights and the terms and conditions were published in a stock exchange release on July 11, 2019. The terms and conditions of the option scheme 2019 are available on the Company’s website at https://investors.remedygames.com/remuneration/.

MORE INFORMATION

Tero Virtala, Chief Executive Officer
Phone: +358 9 435 5040
Email: tero.virtala@remedygames.com

REMEDY IN BRIEF

Remedy Entertainment Plc is a globally successful video game company known for story-driven and visually stunning console and PC games such as Control, Alan Wake and Max Payne. Remedy also develops its own Northlight game engine and game development tools. Founded in 1995 and based in Finland, the company employs over 320 game industry professionals from 32 different countries. www.remedygames.com

DISTRIBUTION

Nasdaq Helsinki Ltd
Key media

www.remedygames.com